Drugs / MK-2118
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03249792 | Sep 2017 → Feb 2023 | cancer, lymphoma | Merck Sharp & Dohme LLC | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-2118 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03249792 ↗ |
| Action | Activate | “Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab” PMID 39846804 ↗ Apr 2025 |
| Route | Other | “MK-2118 when administered via intratumoral (IT) injection” NCT03249792 ↗ |